Mostrando entradas con la etiqueta brentuximab. Mostrar todas las entradas
Mostrando entradas con la etiqueta brentuximab. Mostrar todas las entradas

miércoles, 1 de octubre de 2014

Australian Prescriber Volume 37 Number 5 October 2014



1 de octubre 2014

Índice
Editorial
Pharmaceuticals, pharmacists and profits: the Pharmacy Guild perspective D Quilty
Pharmaceuticals, pharmacists and profits: a health policy perspective P Clarke
Differences in Australian and New Zealand medicines funding policies Z-U-D Babar, A Vitry

Articles
Tricks of the trade in drug promotion: Non-propositional content in pharmaceutical advertising to health professionals P Biegler


Los anuncios de medicamentos de venta bajo receta tienen como objetivo aumentar el uso de los productos. Estos anuncios hacen afirmaciones acerca de las drogas, pero también incluyen contenido no proposicional.
El propósito del contenido no proposicional es fomentar buenos sentimientos acerca de los productos. Esto se puede lograr con las imágenes que cuenta con gente feliz, actividades divertidas o paisajes agradables.
El contenido no proposicional puede llevar a los profesionales de la salud que crean que un fármaco es más beneficioso o más seguro de lo que la evidencia sugiere, aunque ellos nieguen ser influenciados por la publicidad.
Para evitar ser engañados por la publicidad, los profesionales de la salud deberían analizar las afirmaciones que se hacen y compararlas con fuentes independientes de información sobre medicamentos.
Hacer caso omiso de material promocional es otra opción.



Experimental and clinical pharmacology
Janus kinase inhibitors: Mechanisms of action P Kubler
Janus kinase inhibitors in rheumatoid arthritis: Clinical applications J Walker, M Smith
Janus kinase inhibitors in myeloproliferative neoplasms: Clinical applications A Bazargan, C Tam

Letters to the editor

Features
Medicines Safety Update

Dental notes
Topical corticosteroids and oral mucosa

Book review
Stockley’s Drug Interactions, Pocket Companion

New drugs
Aclidinium bromide for chronic obstructive pulmonary disease
Brentuximab vedotin for Hodgkin lymphoma, anaplastic large cell lymphoma
Dolutegravir for HIV infection
Obinutuzumab for chronic lymphocytic leukaemia
Sofosbuvir for hepatitis C


Número completo disponible en http://bit.ly/1vy50vN

jueves, 29 de marzo de 2012

WHO Drug Information Vol. 26, No. 1, 2012




Contenido

Regulatory Focus

Regulation of medicines in China
Paediatric Medicines
Better medicines for children: pharmaceutical formulations
Benznidazole: child-adapted dosage form approved
Use of drugs in paediatric health conditions increasing


Safety and Efficacy Issues

Bevacizumab: severe infectious endophthalmitis and blindness
Ursodeoxycholic acid: serious hepatic events
Simvastatin with amiodarone: dosage review
Fenofibric acid: the ACCORD lipid trial
BCG vaccine: lymphadenitis
Dabigatran etexilate mesylate: bleeding events
Dabigatran etexilate: caution in the elderly and renally impaired
Dabigatran: risk of bleeding
Pneumovax 23®: revaccination recommendations
Somatropin-containing medicines: positive benefit-risk balance
Pholcodine-containing coughs medicines
Antipsychotics in children and adolescents: cardiometabolic reactions
Citalopram hydrobromide: dose dependent QT prolongation
Brentuximab vedotin: new warning and contraindication
Quetiapine: information updated
Aliskiren: cardiovascular and renal events
Natalizumab: progressive multifocal leukoencephalopathy
Boceprevir: HIV protease inhibitor interactions
Bortezomib: fatal if given intrathecally

Regulatory Action and News
Bevacizumab: suspension for metastatic breast cancer
Drotrecogin alfa: withdrawal
Dextropropoxyphene-containing analgesics cancelled
Vemurafenib approved for metastatic or unresectable melanoma
Ecallantide: marketing authorization application withdrawal
Sitagliptin and pioglitazone: marketing authorization application withdrawal
Voclosporin: marketing authorization application withdrawal
Desloratadine: marketing authorization application withdrawal
Electronic CTD implementation
ATC/DDD Classification
ATC/DDD Classification (temporary)
ATC/DDD Classification (final)

Recent Publications, Information and Events
Pharmacovigilance Toolkit

Uppsala Monitoring Centre signals document: increased availability

Learning module: selective serotonin reuptake inhibitors
Medicines access survey
ATC/DDD methodology course
Access and Control Newsletter
Managing access to medicines and health technologies
International Nonproprietary Names



ya está disponible en http://bit.ly/HNssvO